TTRX Overview

Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.

Wall Street analysts forecast TTRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TTRX is6.77 USD with a low forecast of 6.15 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Turn Therapeutics Inc revenue for the last quarter amounts to -1.25M USD, decreased

Turn Therapeutics Inc. EPS for the last quarter amounts to -1645034.00 USD, decreased

Turn Therapeutics Inc (TTRX) has 2 emplpoyees as of June 02 2026.

Today TTRX has the market capitalization of 188.56M USD.